Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.

Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient ...

The applications of AI virtual human technology are rapidly expanding, demonstrating its value in social good and ...

Scientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer and more effective gene ...

Insmed Incorporated (NASDAQ:INSM) is one of the stocks on Jim Cramer’s radar. A caller noted that Cramer has not been quick ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Shares of Capricor Therapeutics CAPR tanked 33% on Friday after it announced that the FDA issued a complete response letter ( ...

Tszkin was diagnosed at the age of one and a half with Duchenne Muscular Dystrophy (DMD), a rare disease, and he has relied ...

Instead of turning inward after the death of his son, Dr. Greg Gulbransen turned outward: toward documentary photography and ...

Advancements in gene editing, strategic partnerships, and supportive regulations fuel global CRISPR adoption across healthcare and agriculture. DELAWARE, DE, UNITED STATES, July 14, 2025 /EINPresswire ...

Panelists discuss how payers seek good return on investment when evaluating expensive gene therapies, creating potential friction when innovative treatments come at significant costs, requiring ...

The enzyme AMPD1 plays a key role in muscle energy production and normal muscular function. Loss of AMPD1 activity due to ...